Q-omics provides the consensus-scored LCE1A profile across patient tissues and cancer cell-line models. LCE1A expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LCE1A is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, LCE1A RNA expression shows 6,365 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, LUSC, and STAD as cancer lineages where LCE1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCE1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCE1A survival associations across molecular data types. LCE1A RNA expression shows survival associations in the most cancer types (16), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCE1A RNA expression–survival associations across cancer types. High LCE1A expression shows unfavorable associations in BRCA, BLCA, MESO, KICH, UCEC and SKCM. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for LCE1A RNA expression.
This table summarizes LCE1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LCE1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCE1A shows lower tumor expression in PRAD and higher tumor expression in LUSC. The LUSC box plot shows higher LCE1A RNA expression in tumor versus normal tissue (log2 FC = +0.376, t-test p = .030).
This table shows molecular features associated with LCE1A in patient tissues and cancer cell lines. In patient samples, LCE1A shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LCE1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and PANCREAS.
